...
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
【24h】

Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.

机译:在D54(p53wt)和U251(p53mut)胶质母细胞瘤细胞系中,DNA拓扑异构酶I毒引起的DNA损伤的聚(ADPR)聚合酶-1信号。

获取原文
获取原文并翻译 | 示例

摘要

Glioblastomas are widely characterised by the mutation of the p53 gene and p53 disruption sensitizes glioblastoma cells to DNA topoisomerase I (TOPO I) inhibitor-mediated apoptosis. We investigated the effects of combined treatments with the DNA topoisomerase I inhibitor Topotecan and the poly(ADPR)polymerase-1 inhibitor NU1025 in D54(p53wt) and U251(p53mut) glioblastoma cell lines. Analysis of cell growth and cell cycle kinetics showed a synergistic anti-proliferative effect of 10 nM TPT and 10 microM NU1025 and a G2/M block of the cell cycle. We also evaluated, the influence of TPT+/-NU1025 treatment on PARP-1 and p53 activity. We got evidences of a TPT-dependent increase of PARP-1 auto-modification level in both the cells. Moreover, in the D54(p53wt) cells we found that in co-treatments NU1025 incremented the TPT-dependent stimulation of p53 transcriptional activity and increased the p21 nuclear amount. Conversely, in U251(p53mut) cells we found that NU1025 incremented the TPT-dependent apoptosis characterised by PARP-1 proteolysis. Our findings suggest that the modulation of PARP-1 can be considered a strategy in the potentiation of the chemotherapeutic action of TOPO I poisons in glioblastoma cells apart from their p53 status.
机译:胶质母细胞瘤的广泛特征是p53基因的突变,p53破坏使胶质母细胞瘤细胞对DNA拓扑异构酶I(TOPO I)抑制剂介导的细胞凋亡敏感。我们研究了DNA拓扑异构酶I抑制剂托泊替康和poly(ADPR)聚合酶-1抑制剂NU1025联合治疗在D54(p53wt)和U251(p53mut)胶质母细胞瘤细胞系中的作用。细胞生长和细胞周期动力学的分析显示了10 nM TPT和10 microM NU1025和细胞周期的G2 / M阻滞的协同抗增殖作用。我们还评估了TPT +/- NU1025处理对PARP-1和p53活性的影响。我们得到了两种细胞中TPT依赖的PARP-1自动修饰水平增加的证据。此外,在D54(p53wt)细胞中,我们发现在共同处理中NU1025增加了TPT依赖性的p53转录活性刺激,并增加了p21核数量。相反,在U251(p53mut)细胞中,我们发现NU1025增加了以PARP-1蛋白水解为特征的TPT依赖性细胞凋亡。我们的发现表明,除了胶体母细胞瘤的p53状态外,还可以考虑调节PARP-1来增强胶质母细胞瘤细胞中TOPO I毒物的化学治疗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号